# Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

> **NCT02782949** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Chronic Atrophic Gastritis
- Gastric Carcinoma

## Interventions

- **DRUG:** Curcumin
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT02782949
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-04
- **Primary completion:** 2022-10-06
- **Final completion:** 2027-04-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782949, "Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02782949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*